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Abstract We investigated success factors for the introduc-
tion of a guideline on recognition of Lynch syndrome in
patients recently diagnosed with colorectal cancer (CRC)
below age 50 or a second CRC below age 70. Pathologists
were asked to start microsatellite instability (MSI) testing
and report to surgeons with the advice to consider genetic
counselling when MSI test or family history was positive.
A multicentre cluster-randomised controlled trial (Clinical-
Trials.gov, number NCT00141466) was performed in 12
pathology laboratories (clusters), serving 29 community
hospitals. All received an introduction to the new guideline.
In the intervention group, surgeons received education and
tumour test result reminders; pathologists were provided
with inclusion criteria cards, an electronic patient inclusion
reminder system and feedback on inclusion. Two hundred
sixty-six CRC patients were eligible for recognition as at
risk for Lynch syndrome. The actual recognition was 18%
more successful in the intervention as compared to the
control arm (77% (120 of 156) compared to 59% (65 of
110)), with an adjusted odds ratio (OR)=2.8 (95%
confidence interval (CI) 1.1–7.0). The electronic reminder
system for pathologists was most strongly associated with
recognition of high-risk patients, OR=4.2 (95% CI 1.7–
10.1). An electronic reminder system for pathologists
The MIPA study group consists of the authors and individuals from
the Radboud University Medical Centre (B. Gordijn, R.P.T.M. Grol,
K.M. Landsbergen, M.F. Niermeijer, H.G. Brunner and P. van
Duijvendijk en R.P. Akkermans) and from the University Medical
Centre Groningen (H. Hollema, J.H. Kleibeuker and R.H. Sijmons).
L. I. Overbeek:M. J. Ligtenberg:N. Hoogerbrugge (*)
Department of Human Genetics 849,
Radboud University Nijmegen Medical Centre,
P.O. Box 9101, 6500 HB Nijmegen, The Netherlands
e-mail: n.hoogerbrugge@antrg.umcn.nl
L. I. Overbeek:R. P. Hermens
Centre for Quality of Care Research,
Radboud University Nijmegen Medical Centre,
Nijmegen, The Netherlands
J. H. van Krieken:M. J. Ligtenberg
Department of Pathology,




Biostatistics and Health Technology Assessment,
Radboud University Nijmegen Medical Centre,
Nijmegen, The Netherlands
M. Casparie




Radboud University Nijmegen Medical Centre,
Nijmegen, The Netherlands
N. Hoogerbrugge
Department of Medical Oncology,
Radboud University Nijmegen Medical Centre,
Nijmegen, The Netherlands
Virchows Arch (2010) 456:653–659
DOI 10.1007/s00428-010-0907-7appeared effective for adherence to a new complex
guideline and will enhance the recognition of Lynch
syndrome.
Keywords Colorectal cancer.HNPCC.Lynch syndrome.
MSI testing.Bethesda criteria
Introduction
In this era of rapidly increasing knowledge on hereditary
cancer, much new evidence needs to be introduced in
clinical practice, often in multidisciplinary teams including
surgeons, pathologists and clinical geneticists. A commonly
used method to achieve awareness is the development of
guidelines for clinical practice. In recent years, many such
guidelines have been published. However, approximately
30–40% of patients do not receive care according to present
scientific evidence, and about 20–25% of care provided is
not needed or is potentially harmful [1]. At present, little is
known about effective strategies for the implementation of
new guidelines in multidisciplinary teams of second-line
medical care [2, 3].
Lynch syndrome, previously referred to as hereditary
non-polyposis colorectal cancer [4], is the most common
type of hereditary CRC and is caused by germ line
inactivation of one of four DNA mismatch repair genes
[5]. Although Lynch syndrome only accounts for up to 5%
of CRCs [6–9], identifying Lynch syndrome is highly
relevant because surveillance substantially reduces morbid-
ity and mortality in family members carrying a mismatch
repair gene mutation [10]. The identification of Lynch
syndrome starts with the recognition of patients at risk for
Lynch syndrome. Traditionally, this is done by the
occurrence of CRC in the family. However, by using
family history, only a small proportion of the expected
number of patients at risk for Lynch syndrome is identified
[11–14]. This is due to small families, unawareness by the
patients of their own family history and suboptimal
registration of family history of cancer by surgeons and
gastroenterologists [11–14]. Recognising patients at risk for
Lynch syndrome can effectively be improved by an
additional procedure using a molecular genetic test on
tumour DNA of a CRC, the so-called microsatellite
instability (MSI) testing [7, 9, 15, 16]. MSI is a hallmark
of a defective mismatch repair system, which results in
differences in length of stretches of simple repeat sequen-
ces, called microsatellites, between normal and tumour
DNA. In Lynch syndrome, virtually all CRCs show MSI.
Although MSI may also occur in sporadic CRC diagnosed
at relatively high age, in the group of patients suspected for
Lynch syndrome, the MSI is predominantly due to genetic
susceptibility [17]. Once patients at risk are identified, this
will lead to identification of more patients with Lynch
syndrome in a highly cost-effective way [15, 18].
A new guideline was developed using MSI testing to
improve recognition ofpatientsatriskfor Lynchsyndromeby
a multidisciplinary team of surgeons, pathologists and clinical
geneticists. In this MSI-testing-indicated-by-a-pathologist
(MIPA) procedure [15], pathologists initiate MSI testing in
a selection of recently diagnosed patients with one of the
following criteria: (1) CRC diagnosed before age 50, (2)
second CRC before age 70, (3) CRC and a Lynch syndrome
associated cancer before age 70 or (4) a colorectal adenoma
with high-grade dysplasia before the age of 40 years [15, 19,
20]. Pathologists report the MSI test result to the surgeon
with the advice to consider referral for genetic counselling in
an outpatient clinic for hereditary cancer when the MSI test
was positive or the family history remained suspicious for
hereditary CRC.
This guideline was proven to be feasible and cost-
effective, includes modern molecular techniques for pathol-
ogists and requires more communication between surgeons,
pathologists and clinical geneticists [15, 21]. To introduce
the MIPA procedure in community hospitals, an implemen-
tation strategy was developed, tailored to barriers found in a
feasibility study [21]. The aim of the present study was to
determine the effects and costs of this implementation. The
secondary aim was to determine which elements of the
implementation were particularly successful.
Patients and methods
Study design
The MIPA study was a cluster-randomised controlled trial in
12 pathology laboratories and the 29 community hospitals in
their catchment area, examining the effectiveness of a
tailored implementation strategy for the MIPA procedure
compared to standard implementation. The Committee on
Research Involving Human Subjects Region Arnhem–
Nijmegen approved the study and waived the need for
written consent from patients (project approval 2004/156).
Patients
Patients recently diagnosed with CRC were eligible for
inclusion. Selection criteria for MSI testing, the MIPA
criteria, were derived from the internationally used
Bethesda guidelines as described [15]. The following
tumours were included as associated with Lynch syndrome:
carcinomas of endometrium, ovary, small bowel, stomach,
biliary tract, upper urinary tract and sebaceous gland [5].
The nationwide electronic registry for pathology in the
Netherlands, PALGA [22], was used for the identification
654 Virchows Arch (2010) 456:653–659of tumours that fulfilled the selection criteria. After closing
the study, 279 patients turned out to have been eligible for
inclusion between September 2005 and December 2006.
Randomisation
Randomisation was done at the level of the pathology
laboratories (clusters).
Intervention
All surgeons and pathologists received written information
on the new procedure for recognition of Lynch syndrome,
as published articles and a guideline. In the intervention
group, pathologists were also provided with electronic
patient inclusion reminders (monthly), feedback on inclu-
sion (every 3 month) and supporting materials such as
small cards with the selection criteria, a list to register MSI-
positive tumours and a folder to save information of MSI
applications. Surgeons received a 1-h interactive small-
scale education session with a lecture and discussion
concerning how and when to tell a patient about a positive
MSI test result. Surgeons also received reminders in the
patient record, consisting of a sticker with a checklist of
three items: (a) MSI result (positive or negative), (b) test
result discussed with patient (yes or no) and (c) patient
referred to cancer genetics clinic (yes or no).
Outcome measures
The primary outcome measure was the percentage of
patients recognised to be at risk for Lynch syndrome.
Recognition was defined as (1) patients with a positive MSI
result who were referred to genetic counselling, or (2)
patients with a negative MSI result, or (3) patients who
were referred to genetic counselling without prior MSI
application by a pathologist. The secondary outcome
measures were the effectiveness of the elements directed
to pathologists and surgeons [2].
Costs of implementation strategy
To gather data about the costs of the elements of the
implementation strategy, surgeons, pathologists and the
research team provided time estimates. These volumes
were multiplied by standardised unit costs [23]. Because
these unit costs were established in 2003, they were
adjusted to 2007 by using the Consumer Price Index as
published by the Central Bureau of Statistics in the
Netherlands (StatLine, www.statline.cbs.nl). Overhead
costs were calculated as 32% of the direct costs to
approximate overhead in health care. All costs were
measured on a per patient basis.
Statistical analysis
Results are reported according to guidelines for reporting
cluster-randomised trials [24]. To guarantee that the laborato-
ries and their hospitals in the intervention group did not differ
in pre-randomisation performance from the laboratories and
hospitals in the control group regarding the outcome measure,
we retrospectively analysed in both groups ‘the percentage of
patients who were referred to genetic counselling without
prior MSI application by a pathologist’. This concerned
patients who were recently diagnosed with CRC in the
participating pathology laboratories between April and De-
cember 2004. We measured only this part of the primary
outcomemeasurebecause MSI testingwas not initiatedbythe
pathologists before the start of the intervention. To examine
the rate of patients referred to genetic counselling, all Dutch
cancer genetics clinics were asked to check whether the
patients selected by PALGA had visited their hospital. The
percentage of patients who received genetic counselling was
30.2% (95% confidence interval (CI) 18.5–41.8%) in the
intervention and 30.4% (95% CI 17.9–42.8%) in the control
group, so the pre-randomisation performance of both groups
was very comparable. To ascertain successful elements of the
implementation strategy, the experiences of pathologists and
surgeons with the elements scored on a six-point Likert scale
were dichotomised into positive or negative experience. Odds
ratios were calculated to describe univariate associations
between each element of the implementation strategy and
the secondary outcome measure. Statistical significance was
set at 5%. Analyses were performed with the SAS system for
Windows V8.2.
Results
Characteristics of clusters and participants
Two hundred seventy-nine patients were eligible for
recognition at risk for Lynch syndrome. In total, 13 patients
were excluded from analysis because insufficient tumour
material was available (n=4); patients had been diagnosed
before with either Lynch syndrome (n=5) or with familial
adenomatous polyposis (n=4). Therefore, the study popu-
lation consisted of 266 patients: 156 patients in the
intervention arm and 110 in the control arm, treated in 17
and 12 community hospitals, respectively. The character-
istics of clusters and participants in the intervention and the
control arm are summarised in Table 1.
Effects of implementation strategy
In Fig. 1, a flow diagram of the recognition of patients at
risk for Lynch syndrome is given. Patients were recognised
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the intervention arm compared to the control arm, 120 out
of 156 (77%) patients and 65 out of 110 (59%) patients,
respectively, with a for clustering adjusted OR=2.8 (95%
CI 1.1–7.0). Pathologists in the intervention arm applied
MSI testing to 116 out of 156 patients (74%) and
pathologists in the control arm to 56 out of 110 patients
(51%). This 23% difference in applying MSI testing
between the intervention and control arm was significant
as well, adjusted OR=4.1 (95% CI 1.3–13.2). Surgeons
from the intervention arm referred as many patients with an
MSI-positive tumour to genetic counselling as those in the
control arm: 14 out of 19 (74%) patients and 7 out of 11
(64%) patients, respectively, OR=1.6 (95% CI 0.09–7.9).
Successful elements of implementation strategy
Five out of six pathologists experienced the electronic
patient inclusion reminder system useful, but none of the
pathologists thought that the feedback on inclusion every
3 months improved application of MSI testing. The
pathologist who scored our electronic reminders as not
effective used a self-developed electronic patient inclusion
reminder system and actually meant that receiving our
172 MSI applications (65%) 
 
Intervention: 116 (74%)  
Control: 56 (51%) 
94 no MSI application (35%) 
 
Intervention: 40 (26%) 
Control: 54 (49%) 
30 positive MSI (11%) 
 
Intervention: 19 (12%) 
Control: 11 (10%) 
142 negative MSI (53%) 
 
Intervention: 97 (62%) 
Control: 45 (41%) 
21 genetic counseling (8%) 
 
Intervention: 14 (9%) 
Control: 7 (6%) 




23 genetic counseling (9%) 
 
Intervention: 10 (6%) 
Control: 13 (12%) 
71 no genetic counseling (27%) 
 
Intervention: 30 (19%) 
Control: 41 (37%) 




-  4 MSI analysis not possible 
-  5 known with Lynch syndrome 
-  4 known with FAP 
9 no genetic counseling (3%) 
 
Intervention: 5 (3%) 
Control: 4 (4%) 
Fig. 1 Flow diagram of the recognition of patients at risk for Lynch syndrome
Table 1 Characteristics of study population
Intervention Control
Clusters:
Pathology laboratories 6 6
Hospitals 17 12
Patients: 156 110
CRC below the age of 50 years 118 (76%) 78 (71%)
Second CRC below the age of 70 years 26 (17%) 18 (16%)
CRC and extracolonic cancer below the age of 70 years
a 7 (4%) 2 (2%)
Colorectal adenoma with high-grade dysplasia below the age of 40 years 5 (3%) 12 (11%)
Age at diagnosis 48.2 (SD=9.8) 46.2 (SD=9.7)
aExtracolonic cancers: malignancies associated with Lynch syndrome (endometrial, ovaries, small bowel, stomach, sebaceous gland, biliary tract and upper
urinary tract)
656 Virchows Arch (2010) 456:653–659electronic reminders was not of additional value. Further-
more, it appeared that two pathology laboratories of the
control arm had developed a reminder system very similar
to the one provided in the intervention arm by themselves.
The availability of an electronic patient inclusion reminder
system was highly associated with the detection of patients
at risk for Lynch syndrome: 156 out of 204 (76%) and 29
out of 62 (47%) with and without an electronic patient
inclusion reminder system, respectively (clustering adjusted
OR=4.2 (95% CI 1.7–10.1)). All pathologists agreed with
the need for a reminder system because only a small subset
(about 13%) of patients with CRC fulfils the criteria for
MSI testing [15] and therefore referring a case for MSI
testing can easily be forgotten. Nevertheless, MSI testing
was applied in only 75% of eligible tumours from
pathology laboratories with an electronic reminder system.
According to interviews with the pathologists, barriers to
application of MSI testing were time constraints and
absence of the pathologist who was primarily responsible
for application of MSI testing. Because the intervention
directed to surgeons was not significantly effective, it was
not possible to determine successful elements at this level.
Costs of implementation strategy
The costs of the elements of the intervention are presented
in Table 2. The total costs per patient at risk for Lynch
syndrome were €78 for the intervention and €11 for the
control arm. The implementation and or running costs of
the electronic patient inclusion reminder system for
pathologists was €27 per patient at risk.
Discussion
This study shows that a simple electronic reminder system
for pathologists markedly increases adherence to the MIPA
procedure, a multidisciplinary guideline for recognition of
CRC patients at high risk for Lynch syndrome. With
surprisingly little effort and at low costs, multidisciplinary
implementation of an entirely novel practice role for
pathologists was improved. The efficiency of counselling
by a clinical geneticist is greatly enhanced when patients
with an MSI-high CRC are being referred for Lynch
syndrome. This is due to the fact that especially patients
with a positive MSI test are at very high risk to be mutation
carriers, whereas a clinical geneticist has little to offer to a
young patient with an MSI-negative CRC, unless the
presence of polyposis or a positive family history clearly
points at a hereditary defect. Our results may have a larger
impact on health care because use of an electronic reminder
system can increase adherence to guidelines of other
hereditary diseases too.
To our knowledge, this is the first study of an
implementation strategy designed to improve the recogni-
tion of patients at risk for Lynch syndrome by tumour
Table 2 Costs of development and execution of elements in euros
Elements Total cost per element Intervention arm Control arm




Dissemination of MIPA method 1,586 792 1
b 1
b





a 39 164 1
c –
Electronic reminders – 4,260 27
d –
Feedback – 568 4
d –
Directed to surgeons:
Education 2,238 6,128 20
c –
Reminders in surgical record 373 1,520 16
e –
Total 4,235 19,428 78
b 11
b
See “Costs of implementation strategy” in the “Patients and method” section
aSupporting materials include: folder, card with selection criteria, list for calling clinicians
bTotal cost of execution of element divided by 600 patients
cTotal cost of execution of element divided by 300 patients
dTotal cost of execution of element divided by 156 patients
eTotal cost of execution of element divided by 39
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procedure, only 30% of the patients at risk for Lynch
syndrome was recognised as such by the traditional
procedure based on signalling familial occurrence of
colorectal cancer [25]. This low number is in line with
other studies showing that family history is insufficient for
recognising patients at risk for Lynch syndrome [11–14].
After introduction of the MIPA procedure in multidisci-
plinary teams including surgeons and pathologists by
written materials, the recognition of patients at risk for
Lynch syndrome was substantially higher, namely 59%. In
the tailored implementation group, this recognition was
even 77%. This difference between control and intervention
g r o u pi sr e l a t i v e l yl a r g e .I nar e v i e wi n c l u d i n g2 3 5
controlled studies, Grimshaw [2] studied the effectiveness
of strategies to implement clinical guidelines. Overall, the
majority of studies observed modest improvements in care
of only 5–10%.
In the present study, the pathologists in the intervention
arm obtained an overview of eligible patients only once a
month. It is expected that the MSI analysis would be
applied even more often, when the pathologist would get a
pop-up with the possibility to initiate MSI testing at the
moment of authorising the pathology report.
The surgeon-directed intervention led to 74% referrals of
patients with an MSI-positive tumour. This was not
significantly larger than in the control group (64%)
probably because of small numbers. It is plausible that a
referral rate of 74% is fairly optimal because not all patients
with an MSI-positive tumour are capable or willing to
receive genetic counselling at the time colorectal cancer is
diagnosed and treated. Our results are in line with previous
data showing that 78% of patients with CRC would accept
genetic counselling shortly after diagnosis [26].
Based on the Bethesda criteria, originally four MIPA
criteria have been defined. However, only two of these
criteria appeared to be fulfilled within our study. Therefore,
we suggest restricting the MIPA criteria to the following
two criteria: (1) CRC diagnosed before age 50 and (2)
second CRC before age 70.
A limitation of the study is that the patient’s visit to a
cancer genetics clinic for genetic counselling was measured
until 6 months after the CRC diagnosis of the last patient. It
is possible that more patients will receive genetic counsel-
ling in the near future. However, as it is unlikely that this
effect differs between the two groups, this will not affect
the conclusion that the intervention leads to a higher rate of
adherence to the guideline.
Our findings indicate that a surprisingly simple and
cheap electronic patient inclusion reminder system for
medical specialists is effective for adherence to a complex
multidisciplinary procedure for recognition of Lynch
syndrome. The implications for health care can be
substantially and are of course not restricted to patients at
risk for Lynch syndrome. Our approach can serve as a
model for implementation of guidelines in other hereditary
diseases.
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